Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia
Open Access
- 22 February 2020
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 188 (6), E101-E105
- https://doi.org/10.1111/bjh.16388
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemiaBlood, 2019
- OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDYHemaSphere, 2019
- Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II TrialJournal of Clinical Oncology, 2018
- Long‐term results of high‐dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experienceBritish Journal of Haematology, 2015
- Growth deceleration in children treated with imatinib for chronic myeloid leukaemiaEuropean Journal of Cancer, 2014
- Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinibAnnals of Hematology, 2013
- Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during pubertyHaematologica, 2012
- Imatinib has adverse effect on growth in children with chronic myeloid leukemiaPediatric Blood & Cancer, 2011
- Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during pubertyThe Lancet, 2008
- Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosingLeukemia & Lymphoma, 2006